EI DuPont de Nemours & Co. (DD) reported
net income of $452 million or 69 cents per share in the third
quarter of 2011 from $367 million or 40 cents per share in the same
quarter of 2010. The profit exceeded the Zacks Consensus Estimate
of 56 cents per share.
The improvement in profit was attributable to higher selling
prices, increased sales volume and currency benefit, partly offset
by higher raw material, energy, and freight costs.
Sales in the quarter grew 32% to $9.2 billion, up from the Zacks
Consensus Estimate of $8.9 billion. The growth in sales reflected a
rise of 1% in sales volume, an increase of 15% in local price, 4%
currency benefit and 12% net increase from portfolio changes. Sales
in the developing markets rose 38%.
Segment Details
In view of the company's expanded business portfolio following
the Danisco acquisition, two new reportable segments have been
added: Industrial Biosciences and Nutrition & Health. The
Industrial Biosciences segment includes Danisco's enzyme business
and DuPont Sorona and Bio-PDO businesses, previously reported in
Other.
The new Nutrition & Health segment contains Danisco's food
ingredients business and DuPont's Nutrition & Health business
previously reported as part of the Agriculture & Nutrition
segment. The former Agriculture & Nutrition segment, now
renamed Agriculture, includes the seed and crop protection
businesses.
Agriculture & Nutrition: Sales
rose 41% to $1.4 billion with a 26% growth in volumes and 15% rise
in selling prices, reflecting a strong, early start to the Latin
American season. For Pioneer seed, volume and price growth was
delivered in both corn and soybeans. Crop Protection sales
increased across all regions and market segments, led by continued
strong demand for Rynaxypyr insecticide.
Pre-tax operating income (PTOI) of $(69) million improved from
$(191) million due to higher sales, partially offset by growth
investments and portfolio changes.
Electronics & Communications:
Sales swelled 20% to $841 million, with an increase of 28% in
selling prices, primarily pass-through of metals prices, and 8%
lower volume. Lower volume reflects destocking in photovoltaics,
and softness in plasma displays and packaging graphics. PTOI of $99
million decreased $27 million on lower volume.
Industrial Biosciences: Sales of $293
million and PTOI of $34 million primarily reflect the acquisition
of Danisco's enzyme business. PTOI included approximately $4
million of amortization expense associated with the fair value
step-up of intangible assets obtained as part of the
acquisition.
Nutrition & Health: Sales of $844
million were up $540 million, principally due to the acquisition of
Danisco's specialty food ingredients business. PTOI of $55 million
increased $45 million reflecting the acquisition and includes $22
million of amortization expense associated with the fair value
step-up of the acquired intangible assets.
Performance Chemicals: Sales escalated
28% to $2.1 billion, with a rise of 29% in selling prices and a
decrease of 1% in volumes. Higher selling prices were driven by
strong global demand for titanium dioxide and fluoropolymers and
pass-through pricing of higher raw material costs for industrial
chemicals. Volume declined in refrigerants and industrial
chemicals. PTOI of $593 million increased $301 million due to
higher selling prices.
Performance Coatings: Sales rose 17%
to $1.1 billion, reflecting a rise of 13% in selling prices and 4%
higher volume. Higher selling prices reflect favorable currency and
pricing actions across all market segments to offset higher raw
material costs. Demand increased for OEM motor vehicle coatings and
remained strong for industrial coatings, particularly in the North
American heavy-duty truck market. PTOI of $72 million increased $8
million on strong sales performance led by refinish.
Performance Materials: Sales went up
11% to $1.7 billion, with a rise of 18% in higher selling prices,
partially offset by 7% lower volume. Higher selling prices
offset higher raw material costs. Lower volume reflects broad-based
channel destocking along with softening in consumer and industrial
markets, and production-related supply issues in ethylene-based
polymers. PTOI of $231 million decreased $50 million on lower
volume.
Safety & Protection: Sales grew
15% to $1.0 billion, with a rise of 8% in higher selling prices and
7% increase from the MECS acquisition. Higher selling prices
primarily reflect pricing actions to offset raw material cost
increases. PTOI of $118 million decreased $16 million on destocking
in industrial markets and higher spending for growth initiatives
including the Cooper River Kevlar expansion, which more than offset
the impact of the acquisition and favorable currency.
Financial Position
DuPont had cash and cash equivalents of $2.8 billion as of
September 30, 2011 compared with $4.3 billion as of December 31,
2010. Long-term borrowings and capital lease obligations amounted
to $12.2billion as of September 30, 2011 versus $10.1 billion as of
December 31, 2010.
As of September 30, 2011, DuPont had net cash flow of $431
million from operating activities versus $644 million as of June
30, 2011. Meanwhile, capital expenditures increased to $1.2 billion
from $741 million in the prior quarter.
Outlook
DuPont upgraded its full-year 2011 earnings outlook to
$3.97–$4.05 per share from its previous forecast of $3.90–$4.05 per
share. This revision was attributable to the company’s strong
earnings results.
Expectations for the fourth quarter include slowing global
growth, some destocking, and the recognition that a portion of
Agriculture sales in Latin America was shifted to the third quarter
by the early start of the planting season.
DuPont is a global chemical and life sciences company, employing
more than 60,000 people worldwide with a diverse array of product
offerings. With over 21,000 patents and 15,000 patent applications
worldwide, DuPont sells its products in diverse markets, such as
transportation, construction, apparel, agriculture, nutrition and
health, packaging and electronics markets.
DuPont faces stiff competition from BASF SE
(BASFY) and The Dow Chemical Company (DOW).
The company currently retains a Zacks #3 Rank, which translates
into short-term Hold rating. In addition, we reiterate our
long-term Outperform recommendation on the stock.
BASF AG-ADR NEW (BASFY): Free Stock Analysis Report
DU PONT (EI) DE (DD): Free Stock Analysis Report
DOW CHEMICAL (DOW): Free Stock Analysis Report
Zacks Investment Research
Dow (NYSE:DOW)
Historical Stock Chart
From May 2024 to Jun 2024
Dow (NYSE:DOW)
Historical Stock Chart
From Jun 2023 to Jun 2024